This fantastic presentation by Dr. John Carmichael, Distinguished Professor of Clinical Medicine at the University of Southern California and Co-director of the USC Pituitary Center focuses on the controversies arising from the clinical dilemmas present in treating a complicated condition like acromegaly.
Acromegaly
Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
A story about a nurse with acromegaly
Meet Laura Cheng. Laura is a nurse. She has acromegaly. She works as a clinical nurse and is currently enrolled in the endocrine program at Duke University.
Acromegaly: clinical insights in a new book
This book, edited by world-renowned clinicians and editors Dr. Manish Aghi and Dr. Lewis Blevins, delivers a guide to medical decision-making on diagnosing and treating acromegaly.
Another great support resource for people with acromegaly
We take advantage of Acromegaly Day, coming up on November 1, to highlight resources from industry partners. The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. PALs work with
Acromegaly: A Rational Approach to Medical Management of Patients with Residual and Recurrent Disease.
This is a highly informative presentation on the subtleties of the medical management of this complicated disease direct from the clinical practices of one of the best most experienced physicians treating acromegaly patients today.
Supporting a new diagnosis of Acromegaly
We continue to showcase Pfizer’s new series on patient support. This brochure offers great advice on how to deal with a new acromegaly diagnosis. The materials provide valuable content given the importance of proper disease
When 304 people, including 128 living with acromegaly, gather to talk about the disease, good things can happen.
In January 2021, the Acromegaly Community, a US-based patient advocacy organization, organized and participated in an externally lead patient focus drug development meeting. The EL-PFDD initiative is a Food and Drug Administration (FDA) effort to systematically
Acromegaly: the last 30 years
In this Podcast, Dr. Blevins gives us a perspective of the last 30 years on the developments in this field. Like many other conditions, the advances in therapy, imaging, surgery techniques, diagnostic testing, and clinical knowledge have been nothing short of remarkable.
Canada to Mexico: Rare pituitary disease patient bikes the 1845-mile Pacific Coast Highway
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
A new drug for acromegaly: an insider’s look at the clinical trial
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
A Conversation with Acromegaly Patient Advocates
Music Composed and Produced by, MusicWorksFoundry(TM) (ASCAP). All Rights Reserved.
Big news for acromegaly at Crinetics
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Pregnancy and acromegaly
Acromegaly: what to do with medical treatment during pregnancy and the options available today.